Oncology Research Reagents: Antibodies, Proteins & Kits for Cancer Research

Release date: 2026-04-10 View count: 24

Cancer research has entered an era defined by precision targeting — immune checkpoint blockade, antibody-drug conjugates, bispecific T cell engagers, and tumor microenvironment reprogramming. Each of these approaches depends on high-quality research reagents: validated antibodies for target detection and functional assays, recombinant proteins as antigens and standards, and ELISA kits for bioanalytical quantification.

abinScience provides over 4,900 oncology-relevant products spanning antibodies, recombinant proteins, research biosimilar reference antibodies, and assay kits — all from one original manufacturer. This page serves as your central hub for navigating oncology research reagents by therapeutic area, target class, or cancer type.

Reagents by Therapeutic Area

Therapeutic Area	Key Targets	Products	Product Types
Immune Checkpoints	PD-1, PD-L1, CTLA-4, LAG-3, TIGIT, TIM-3, CD47, B7-H3	1,170+	Antibodies, Proteins, Biosimilars
ADC Targets	HER2, TROP2, Claudin 18.2, Nectin-4, CD33, CD22, BCMA, Mesothelin	1,500+	Antibodies, Proteins, Biosimilars
Tumor Microenvironment	CD68, CD163, CSF1R, Foxp3, TGF-β, CXCR4, IDO1, CD25	570+	Antibodies, Proteins
T Cell & NK Cell Markers	CD3, CD4, CD8, CD19, CD20, OX40, 4-1BB, CD27, CD56	3,300+	Antibodies, Proteins, Biosimilars
Cancer Signaling Pathways	EGFR, KRAS, BRAF, ALK, ROS1, MET, RET, FGFR, PIK3CA, mTOR	920+	Antibodies, Proteins
Research Biosimilars	Pembrolizumab, Nivolumab, Trastuzumab, Rituximab, Atezolizumab, Bevacizumab + 200 more	2,700+	Research-grade therapeutic antibodies for PK/ADA assays

Browse by Cancer Type

abinScience organizes oncology reagents by 20 cancer types, each with curated target lists, validated antibodies, and research biosimilar reference standards. Select your cancer type to see available reagents:

Cancer Type	Products	Key Targets
Colorectal Cancer	1,505	EGFR, KRAS, MSI/MMR, CEA, VEGF
Lymphoma	1,092	CD20, CD19, CD30, CD22, PD-1
Melanoma	975	BRAF, PD-1, CTLA-4, SOX10, MITF
Lung Cancer	766	EGFR, ALK, PD-L1, KRAS, ROS1, MET
Sarcoma	711	KIT, PDGFRA, MDM2, CDK4
AML	683	CD33, FLT3, IDH1/2, CD123
Gastric Cancer	579	HER2, Claudin 18.2, PD-L1, VEGFR-2
Pancreatic Cancer	538	KRAS, Mesothelin, Claudin 18.2, CA19-9
Cervical Cancer	528	HPV E6/E7, PD-L1, p16, TROP2
Ovarian Cancer	497	BRCA1/2, CA125, FOLR1, HE4, PD-L1
Bladder Cancer	413	PD-L1, FGFR3, Nectin-4, EGFR
Breast Cancer	370	HER2, ER, PR, BRCA, TROP2, Ki-67
RCC	411	VEGF, PD-1, CTLA-4, mTOR, HIF
HCC	346	AFP, GPC3, PD-L1, VEGFR-2
Multiple Myeloma	255	BCMA, CD38, SLAMF7, GPRC5D
GBM	229	EGFR/EGFRvIII, IDH1, MGMT, GFAP
Prostate Cancer	191	PSA, PSMA, AR, BRCA2, PTEN

Why Choose abinScience for Oncology Research?

Original manufacturer pricing. As the original manufacturer (not a reseller), abinScience offers direct pricing without distributor markups — typically 30–50% below comparable products from catalog antibody companies.

Protein→Antibody→Kit full target chain. For many oncology targets, we offer the complete research toolchain: recombinant antigen proteins, matched detection and neutralizing antibodies, and ELISA kits for quantitative measurement — all produced in-house with consistent quality.

2,700+ research biosimilar antibodies. The largest research-grade collection of therapeutic antibody sequences covering approved and clinical-stage immuno-oncology drugs — essential for PK/ADA bioanalytical assays and preclinical benchmarking.

Catalog-to-CRO upgrade path. Need custom antibody development, stable cell lines, or SPR/BLI characterization? AtaGenix's CRO services integrate seamlessly with abinScience catalog products — from discovery to production under one roof.

Application-Specific Guides

Looking for protocol guidance? Our technical resource library includes step-by-step guides for every major application used in oncology research:

Application	Guide
IHC (tumor tissue)	IHC Protocol Guide & IHC Troubleshooting Guide \| IHC Panel Design for Cancer Diagnosis
Flow Cytometry (immune phenotyping)	Flow Cytometry Staining Protocol & Fluorochrome Selection Guide \| Flow Cytometry for TIL Analysis
ELISA (PK/ADA, biomarker quantification)	ELISA Protocol Guide \| PK/ADA Assay Development
IF (co-localization, multiplex)	IF/ICC Staining Protocol
Neutralization (checkpoint blocking)	Neutralization Assay Guide
Research Biosimilars	Research Biosimilar Antibodies Explained

References

1. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059

2. Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56-61. doi: 10.1126/science.aaa8172

3. Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18(6):327-344. doi: 10.1038/s41571-021-00470-8

4,900+ Oncology Research Reagents

Antibodies, proteins, biosimilars, and kits — covering immune checkpoints, ADC targets, signaling pathways, and 20 cancer types. Original manufacturer quality at competitive prices.

Browse Oncology Products →

All products are for research use only (RUO). For technical support, contact order@abinscience.com.

Recommendation